pharma · Hemophilia A · Hemophilia A or B With Inhibitors
Baxalta Innovations
Baxalta Innovations GmbH
Baxalta Innovations clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Illinois, USA
- Founded
- 2015
- Employees
- 475
- Programs
- 6
- Drugs
- 12
- Patents
- 1
Baxalta Innovations projects
6 ClinicalTrials.gov programs sponsored by Baxalta Innovations.
Baxalta Innovations has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
071102
Baxalta Innovations GmbH
Hereditary severe von Willebrand Disease in children
1 trial -
090701
Baxalta Innovations GmbH
Hemophilia A or B With Inhibitors
1 trial -
Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
Baxalta Innovations GmbH
Hemophilia A
1 trial -
BAX855
Baxalta Innovations GmbH
Hemophilia A
1 trial -
TAK-755-3002
Baxalta Innovations GmbH
Congenital Thrombotic thrombocytopenic purpura (cTTP)
1 trial -
TAK-881
Baxalta Innovations GmbH
Primary Immunodeficiency Diseases
1 trial
Frequently asked questions
How many clinical projects does Baxalta Innovations have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.